Application of the Insect Cell-Baculovirus Expression Vector System in Adeno-Associated Viral Production
Source abstract
Abstract
Insect Cell-Baculovirus Expression Vector System (IC-BEVS) is an efficient protein expression platform, which is famous for its high-level expression of complex protein in insect cells. The system is based on baculoviruses such as Autographa californica multiple nucleopolyhedrovirus (AcMNPV), and the expression efficiency of the target proteins has been significantly improved by optimizing the viral vectors and cell lines. In recent years, IC-BEVS have shown great potential for Adeno-Associated Virus (AAV) production, particularly excelling in AAV structural protein expression and recombinant AAV production. The system not only improves the yield and purity of AAV, but also shortens the production cycle, providing an efficient and reliable tool for gene therapy. However, the system also has some challenges, including protein modification differences, limitations in expression levels, and production costs. This paper reviews the development of the insect baculovirus expression system, its application in AAV production, and its prospects in gene therapy, aiming to provide a systematic reference and outlook for research in related fields.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Viral Infectious Diseases and Gene Expression in Insects · Virus-based gene therapy research · CRISPR and Genetic Engineering
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Life Science and Chemistry, Hunan University of Technology, Zhuzhou 412007, China
State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, Key Laboratory of Magnetic Resonance in Biological Systems, Wuhan Center for Magnetic Resonance, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences, Wuhan 430071, China
Funding
Hunan Provincial Department of Education · General Project of Hunan Science and Technology Department · General Project of National Natural Science Foundation of China · National Natural Science Foundation of China for Original Exploration Project
References (99)
Show source-provided references
1. AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset10.1038/s41593-021-00969-4 ↗
2. Bower, J.J., Song, L., Bastola, P., and Hirsch, M.L. (2021). Harnessing the Natural Biology of Adeno-Associated Virus to Enhance the Efficacy of Cancer Gene Therapy. Viruses, 13.10.3390/v13071205 ↗
3. Adeno-associated virus vector as a platform for gene therapy delivery10.1038/s41573-019-0012-9 ↗
4. Adeno-Associated Virus at 50: A Golden Anniversary of Discovery, Research, and Gene Therapy Success—A Personal Perspective10.1089/hum.2015.025 ↗
5. The Adeno-Associated Virus Genome Packaging Puzzle
6. Sen, D. (2014). Improving clinical efficacy of adeno associated vectors by rational capsid bioengineering. J. Biomed. Sci., 21.10.1186/s12929-014-0103-1 ↗
7. Adeno-associated viral vector integration: Implications for long-term efficacy and safety10.1016/j.jtha.2024.07.012 ↗
8. Adeno-Associated Virus Serotype-Specific Inverted Terminal Repeat Sequence Role in Vector Transgene Expression10.1089/hum.2019.274 ↗
9. Kuz, C.A., McFarlin, S., and Qiu, J. (2024). The Expression and Function of the Small Nonstructural Proteins of Adeno-Associated Viruses (AAVs). Viruses, 16.10.3390/v16081215 ↗
10. The membrane associated accessory protein is an adeno-associated viral egress factor10.1038/s41467-021-26485-4 ↗
11. Galibert, L., Hyvonen, A., Eriksson, R.A.E., Mattola, S., Aho, V., Salminen, S., Albers, J.D., Peltola, S.K., Weman, S., and Nieminen, T. (2021). Functional roles of the membrane-associated AAV protein MAAP. Sci. Rep., 11.10.1038/s41598-021-01220-7 ↗
12. Role of the membrane-associated accessory protein (MAAP) in adeno-associated virus (AAV) infection10.1128/jvi.00633-24 ↗
13. Iglesias, C.F., Ristovski, M., Bolic, M., and Cuperlovic-Culf, M. (2023). rAAV Manufacturing: The Challenges of Soft Sensing during Upstream Processing. Bioengineering, 10.10.3390/bioengineering10020229 ↗
14. Evaluating the state of the science for adeno-associated virus integration: An integrated perspective10.1016/j.ymthe.2022.06.004 ↗
15. Adeno-Associated Virus Engineering and Load Strategy for Tropism Modification, Immune Evasion and Enhanced Transgene Expression10.2147/IJN.S459905 ↗
16. Sorroza-Martinez, L., Pelletier, M., Guay, D., and Gaillet, B. (2024). Recent Advances in Therapeutics and Manufacturing Processes of Recombinant Adeno-Associated Virus for the Treatment of Lung Diseases. Curr. Gene Ther., 25, Online ahead of print.10.2174/0115665232294935240826061311 ↗
17. Adeno-associated virus–based gene therapy treats inflammatory kidney disease in mice10.1172/JCI174722 ↗
18. Liu, D., Li, T., Liu, L., Che, X., Li, X., Liu, C., and Wu, G. Adeno-Associated Virus Therapies: Pioneering Solutions for Human Genetic Diseases. Cytokine Growth Factor. Rev., 2024. in press.10.1016/j.cytogfr.2024.09.003 ↗
19. Li, L., Vasan, L., Kartono, B., Clifford, K., Attarpour, A., Sharma, R., Mandrozos, M., Kim, A., Zhao, W., and Belotserkovsky, A. (2023). Advances in Recombinant Adeno-Associated Virus Vectors for Neurodegenerative Diseases. Biomedicines, 11.10.3390/biomedicines11102725 ↗
20. Recombinant Adeno-Associated Virus Vectors for Gene Therapy of the Central Nervous System: Delivery Routes and Clinical Aspects
21. Utilizing adeno-associated virus as a vector in treating genetic disorders or human cancers10.1002/iub.2896 ↗
22. Issa, S.S., Shaimardanova, A.A., Solovyeva, V.V., and Rizvanov, A.A. (2023). Various AAV Serotypes and Their Applications in Gene Therapy: An Overview. Cells, 12.10.3390/cells12050785 ↗
23. Current Clinical Applications of In Vivo Gene Therapy with AAVs10.1016/j.ymthe.2020.12.007 ↗
24. AAV mediated gene therapy for haemophilia B: From the early attempts to modern trials10.1016/j.thromres.2020.12.033 ↗
25. Alsalloum, A., Gornostal, E., Mingaleva, N., Pavlov, R., Kuznetsova, E., Antonova, E., Nadzhafova, A., Kolotova, D., Kadyshev, V., and Mityaeva, O. (2024). A Comparative Analysis of Models for AAV-Mediated Gene Therapy for Inherited Retinal Diseases. Cells, 13.10.3390/cells13201706 ↗
26. AAV gene therapy for Duchenne Muscular Dystrophy: Lessons learned from a phase 3 trial10.1038/s41434-024-00494-6 ↗
27. Merten, O.-W. (2024). Development of Stable Packaging and Producer Cell Lines for the Production of AAV Vectors. Microorganisms, 12.10.3390/microorganisms12020384 ↗
28. Adeno-associated virus as a delivery vector for gene therapy of human diseases10.1038/s41392-024-01780-w ↗
29. Destro, F., Wu, W., Srinivasan, P., Joseph, J., Bal, V., Neufeld, C., Wolfrum, J.M., Manalis, S.R., Sinskey, A.J., and Springs, S.L. (2024). The state of technological advancement to address challenges in the manufacture of rAAV gene therapies. Biotechnol. Adv., 76.10.1016/j.biotechadv.2024.108433 ↗
30. Producing high-quantity and high-quality recombinant adeno-associated virus by low-cis triple transfection10.1016/j.omtm.2024.101230 ↗
31. Baculovirus: An insect-derived vector for diverse gene transfer applications10.1038/mt.2012.286 ↗
32. A robust and flexible baculovirus-insect cell system for AAV vector production with improved yield, capsid ratios and potency10.1016/j.omtm.2024.101228 ↗
33. Characterization of Viral Genome Encapsidated in Adeno-associated Recombinant Vectors Produced in Yeast Saccharomyces cerevisiae10.1007/s12033-020-00294-4 ↗
34. Aponte-Ubillus, J.J., Barajas, D., Sterling, H., Aghajanirefah, A., Bardliving, C., Peltier, J., Shamlou, P., Roy, M., and Gold, D. (2020). Proteome profiling and vector yield optimization in a recombinant adeno-associated virus-producing yeast model. Microbiologyopen, 9.10.1002/mbo3.1136 ↗
35. Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells10.1016/j.ymthe.2023.11.022 ↗
36. Temporal insights into molecular and cellular responses during rAAV production in HEK293T cells10.1016/j.omtm.2024.101278 ↗
37. Generation of Complex Protein Structures by Coinfection with High-Quality Recombinant Baculovirus10.1007/978-1-0716-3961-0_10 ↗
38. Recombinant AAV Production10.1007/978-1-0716-3961-0_14 ↗
39. Baculovirus Expression Systems for Recombinant Protein Production in Insect Cells10.2174/187220809787172669 ↗
40. Engineering of the baculovirus expression system for optimized protein production10.1007/s00253-018-9474-7 ↗
41. Pidre, M.L., Arrias, P.N., Amoros Morales, L.C., and Romanowski, V. (2022). The Magic Staff: A Comprehensive Overview of Baculovirus-Based Technologies Applied to Human and Animal Health. Viruses, 15.10.3390/v15010080 ↗
42. Production of Recombinant PRMT Proteins using the Baculovirus Expression Vector System
43. Bissett, S.L., and Roy, P. (2024). Multi-Gene Recombinant Baculovirus Expression Systems: From Inception to Contemporary Applications. Viruses, 16.10.3390/v16040492 ↗
44. Optimizing the baculovirus expression vector system10.1016/j.ymeth.2011.06.011 ↗
45. Ono, C., Okamoto, T., Abe, T., and Matsuura, Y. (2018). Baculovirus as a Tool for Gene Delivery and Gene Therapy. Viruses, 10.10.3390/v10090510 ↗
46. Pijlman, G.P., Grose, C., Hick, T.A.H., Breukink, H.E., van den Braak, R., Abbo, S.R., Geertsema, C., van Oers, M.M., Martens, D.E., and Esposito, D. (2020). Relocation of the attTn7 Transgene Insertion Site in Bacmid DNA Enhances Baculovirus Genome Stability and Recombinant Protein Expression in Insect Cells. Viruses, 12.10.3390/v12121448 ↗
47. Baculovirus expression system for heterologous multiprotein complexes10.1038/nbt1036 ↗
48. Recent Developments in the Use of Baculovirus Expression Vectors10.21775/cimb.034.215 ↗
49. Progress in vaccine development based on baculovirus expression vector system
50. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age10.1016/j.vaccine.2011.01.039 ↗
51. Characterization of an Sf-rhabdovirus-negative Spodoptera frugiperda cell line as an alternative host for recombinant protein production in the baculovirus-insect cell system10.1016/j.pep.2016.02.014 ↗
52. Hong, M., Li, T., Xue, W., Zhang, S., Cui, L., Wang, H., Zhang, Y., Zhou, L., Gu, Y., and Xia, N. (2022). Genetic engineering of baculovirus-insect cell system to improve protein production. Front. Bioeng. Biotechnol., 10.10.3389/fbioe.2022.994743 ↗
53. Improving the baculovirus expression vector system with vankyrin-enhanced technology10.1002/btpr.2516 ↗
54. Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector
55. Overview of the Baculovirus Expression System
56. Baculovirus-driven protein expression in insect cells: A benchmarking study10.1016/j.jsb.2018.03.004 ↗
57. Membrane Protein Production in Insect Cells10.1007/978-1-0716-2368-8_12 ↗
58. Improved pFastBac™ donor plasmid vectors for higher protein production using the Bac-to-Bac® baculovirus expression vector system10.1016/j.jbiotec.2017.06.397 ↗
59. Engineering the transposition-based baculovirus expression vector system for higher efficiency protein production from insect cells10.1016/j.jbiotec.2016.09.002 ↗
60. The MultiBac BEVS: Basics, applications, performance and recent developments10.1016/bs.mie.2021.06.018 ↗
61. High-throughput baculovirus expression in insect cells10.1007/978-1-61779-433-9_33 ↗
62. Preparation of recombinant baculoviruses with the BVboost system10.1101/pdb.prot5181 ↗
63. Molecular design for recombinant adeno-associated virus (rAAV) vector production10.1007/s00253-017-8670-1 ↗
64. Insect Cells as a Factory to Produce Adeno-Associated Virus Type 2 Vectors10.1089/10430340260355347 ↗
65. Successful Production of Pseudotyped rAAV Vectors Using a Modified Baculovirus Expression System10.1016/j.ymthe.2005.08.018 ↗
66. Scalable generation of high-titer recombinant adeno-associated virus type 5 in insect cells10.1128/JVI.80.4.1874-1885.2006 ↗
67. A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells10.1038/mt.2009.128 ↗
68. Intron splicing-mediated expression of AAV Rep and Cap genes and production of AAV vectors in insect cells10.1038/mt.2008.35 ↗
69. An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells10.1073/pnas.0810614106 ↗
70. OneBac: Platform for scalable and high-titer production of adeno-associated virus serotype 1-12 vectors for gene therapy10.1089/hum.2013.184 ↗
71. OneBac 2.0: Sf9 Cell Lines for Production of AAV1, AAV2, and AAV8 Vectors with Minimal Encapsidation of Foreign DNA10.1089/hgtb.2016.164 ↗
72. OneBac 2.0: Sf9 Cell Lines for Production of AAV5 Vectors with Enhanced Infectivity and Minimal Encapsidation of Foreign DNA10.1089/hum.2015.050 ↗
73. Development of Versatile and Flexible Sf9 Packaging Cell Line-Dependent OneBac System for Large-Scale Recombinant Adeno-Associated Virus Production10.1089/hgtb.2019.123 ↗
74. A Recombinant Baculovirus Efficiently Generates Recombinant Adeno-Associated Virus Vectors in Cultured Insect Cells and Larvae10.1016/j.omtm.2018.05.005 ↗
75. Popularizing Recombinant Baculovirus-derived OneBac System for Laboratory Production of all Recombinant Adeno-associated Virus Vector Serotypes10.2174/1566523221666210118111657 ↗
76. Galibert, L., Jacob, A., Savy, A., Dickx, Y., Bonnin, D., Lecomte, C., Rivollet, L., Sanatine, P., Boutin Fontaine, M., and Le Bec, C. (2021). Monobac System–A Single Baculovirus for the Production of rAAV. Microorganisms, 9.10.3390/microorganisms9091799 ↗
77. Joshi, P.R., Venereo-Sanchez, A., Chahal, P.S., and Kamen, A.A. (2021). Advancements in molecular design and bioprocessing of recombinant adeno-associated virus gene delivery vectors using the insect-cell baculovirus expression platform. Biotechnol. J., 16.10.1002/biot.202000021 ↗
78. AAV vector production: State of the art developments and remaining challenges10.18609/cgti.2016.067 ↗
79. Latest developments in the large-scale production of adeno-associated virus vectors in insect cells toward the treatment of neuromuscular diseases10.1016/j.jip.2011.05.008 ↗
80. Production of rAAV by plasmid transfection induces antiviral and inflammatory responses in suspension HEK293 cells10.1016/j.omtm.2023.01.002 ↗
81. AAV Production Using Baculovirus Expression Vector System10.1007/978-1-4939-9065-8_5 ↗
82. Large-scale recombinant adeno-associated virus production10.1093/hmg/ddr141 ↗
83. Significant Differences in Capsid Properties and Potency Between Adeno-Associated Virus Vectors Produced in Sf9 and HEK293 Cells10.1089/hum.2022.116 ↗
84. Hong, Q., Liu, J., Wei, Y., and Wei, X. (2023). Application of Baculovirus Expression Vector System (BEVS) in Vaccine Development. Vaccines, 11.10.3390/vaccines11071218 ↗
85. Methods Matter: Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors10.1016/j.omtm.2020.05.018 ↗
86. Human and Insect Cell-Produced Recombinant Adeno-Associated Viruses Show Differences in Genome Heterogeneity10.1089/hum.2022.050 ↗
87. Kondratov, O., and Zolotukhin, S. (2023). Exploring the Comprehensive Kozak Sequence Landscape for AAV Production in Sf9 System. Viruses, 15.10.3390/v15101983 ↗
88. Endgame: Glybera Finally Recommended for Approval as the First Gene Therapy Drug in the European Union10.1038/mt.2012.194 ↗
89. Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?10.1146/annurev-virology-092818-015530 ↗
90. Onasemnogene Abeparvovec: First Global Approval10.1007/s40265-019-01162-5 ↗
91. Eladocagene Exuparvovec: First Approval
92. Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: Expert guidance for clinical practice10.1182/bloodadvances.2024013750 ↗
93. Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B10.1080/17474086.2023.2276206 ↗
94. Delandistrogene Moxeparvovec: First Approval10.1007/s40265-023-01929-x ↗
95. Fidanacogene Elaparvovec: First Approval10.1007/s40265-024-02017-4 ↗
96. Preclinical Development and Characterization of Novel Adeno-Associated Viral Vectors for the Treatment of Lipoprotein Lipase Deficiency10.1089/hum.2023.075 ↗
97. Valoctocogene Roxaparvovec: First Approval10.1007/s40265-022-01788-y ↗
98. Shen, W., Liu, S., and Ou, L. (2022). rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis. Front. Immunol., 13.10.3389/fimmu.2022.1001263 ↗
99. Kong, X., Li, T., and Yang, H. (2024). AAV-mediated gene therapies by miniature gene editing tools. Sci. China Life Sci.10.1007/s11427-023-2608-5 ↗